Get started
Author

Haruna Tomono

ORCID: 0009-0007-2371-8647
Observed ORCID: 0009-0007-2371-8647
OpenAlex ID: A5111218951
Sevabertinib, a Reversible HER2 Inhibitor with Activity in Lung Cancer
2025 · Franziska Siegel, Stephan Siegel, et al. · Cancer Discovery · 34
Table S1 from Sevabertinib, a Reversible HER2 Inhibitor with Activity in Lung Cancer
2026 · Franziska Siegel, Stephan Siegel, et al. · 1
Supplementary Methods 1 from Sevabertinib, a Reversible HER2 Inhibitor with Activity in Lung Cancer
2026 · Franziska Siegel, Stephan Siegel, et al. · 1
Host cell protein detection via surfactant-assisted acid precipitation
2025 · Haruna Tomono, Yue Su, et al. · Journal of Pharmaceutical Sciences · 1
Plasma and Kidney Proteome Profiling Combined with Laser Capture Microdissection Reveal Large Increases in Immunoglobulins with Age
2024 · Leanne J. G. Chan, Niclas Olsson, et al. · Proteomes · 1
PDF
Abstract 1980: Pan-cancer LINE-1 retrotransposition landscapes in TCGA whole-genome sequences.
2026 · Beomki Lee, Ryul Kim, et al. · Cancer Research
Abstract 2001: Discovery of coding and non-coding driver mutations across >8,000 TCGA whole genomes.
2026 · David Lehotzky, Ron Solan, et al. · Cancer Research
Abstract 1986: The pan-cancer landscape of chromosome Y alterations.
2026 · Luis Antonio Corchete Sanchez, Chunyang Bao, et al. · Cancer Research
Abstract 492: Uncovering therapeutically targetable mutations from The Cancer Genome Atlas (TCGA) whole-genome datasets.
2026 · Ryul Kim, Chunyang Bao, et al. · Cancer Research
Abstract 1990: Pan-cancer PCR-free whole-genome sequencing refines the somatic driver landscape beyond exome sequencing alone.
2026 · Gengchao Wang, David I Heiman, et al. · Cancer Research
Abstract 7270: Comprehensive mutation profiling from The Cancer Genome Atlas (TCGA) whole-genome sequencing datasets
2026 · Chunyang Bao, Hansol Park, et al. · Cancer Research
Abstract 3247: Origins of structural variant junctional insertions across >8,000 TCGA whole genomes
2026 · Youyun Zheng, Gregory Raskind, et al. · Cancer Research
Abstract 5934: Genomic signatures of chromosomal instability from a pan-cancer landscape of haplotype-specific copy-number alterations
2026 · Chunyang Bao, Matthew Leventhal, et al. · Cancer Research
Abstract 1991: Germline predisposition in The Cancer Genome Atlas (TCGA) whole-genome sequencing datasets.
2026 · Ryul Kim, Owen Hirschi, et al. · Cancer Research
Abstract 1989: Systematic discovery and classification of structural variant drivers across >8,000 TCGA whole genomes.
2026 · Antonia Kowalewski, Xavi Loinaz, et al. · Cancer Research
Abstract 7274: Structural variant signature discovery across >8,000 TCGA whole genomes using QuantHDP
2026 · Gregory Raskind, Youyun Zheng, et al. · Cancer Research
Abstract 6881: Fast and cost-effective cloud-based pipelines to analyze cancer sequencing data.
2026 · Sam Wiseman, Samantha Van Seters, et al. · Cancer Research
Abstract 1977: Whole-genome sequencing of >8,000 TCGA samples reveals diverse and atypical spectra of homologous recombination deficiency in primary human cancers.
2026 · Joonoh Lim, Chunyang Bao, et al. · Cancer Research
Abstract 7268: AI-Driven stratification of cancer patients using The Cancer Genome Atlas whole-genome sequencing data
2026 · Jonghoon Lee, Chunyang Bao, et al. · Cancer Research
Abstract 1978: Copy number analysis of regulatory regions reveal recurrent promoter/enhancer somatic copy number alterations across >8,000 TCGA samples.
2026 · Haruna Tomono, Chunyang Bao, et al. · Cancer Research
Abstract 2002: The landscape of X chromosome copy number alterations in cancer.
2026 · Matthew Joseph Leventhal, Chunyang Bao, et al. · Cancer Research
Table S5 from Sevabertinib, a Reversible HER2 Inhibitor with Activity in Lung Cancer
2026 · Franziska Siegel, Stephan Siegel, et al.
Data from Sevabertinib, a Reversible HER2 Inhibitor with Activity in Lung Cancer
2026 · Franziska Siegel, Stephan Siegel, et al.
Table S2 from Sevabertinib, a Reversible HER2 Inhibitor with Activity in Lung Cancer
2026 · Franziska Siegel, Stephan Siegel, et al.
Table S3 from Sevabertinib, a Reversible HER2 Inhibitor with Activity in Lung Cancer
2026 · Franziska Siegel, Stephan Siegel, et al.
Works count: 35
Citation count: 38
H-index: 1
I10-index: 1
Year
Topic
Type